Business Description
GeNeuro SA
ISIN : CH0308403085
Compare
Compare
Traded in other countries / regions
GNRO.FranceGEM.GermanyGNROp.UKGNRRF.USA IPO Date
2016-04-21Description
GeNeuro SA is a clinical-stage biopharmaceutical company focused on understanding and stopping causal factors driving the progression of neurodegenerative and autoimmune diseases. The company's therapeutic candidate, temelimab, is a humanized monoclonal antibody that neutralizes a pathogenic protein of the HERV-W family (W-ENV).
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.14 | |||||
| Equity-to-Asset | -2.17 | |||||
| Debt-to-Equity | -0.97 | |||||
| Debt-to-EBITDA | -0.95 | |||||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -9.8 | |||||
| 3-Year EPS without NRI Growth Rate | -11.4 | |||||
| 3-Year FCF Growth Rate | -4.3 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 49.69 | |||||
| 9-Day RSI | 53.12 | |||||
| 14-Day RSI | 53.73 | |||||
| 3-1 Month Momentum % | 9.09 | |||||
| 6-1 Month Momentum % | -97.59 | |||||
| 12-1 Month Momentum % | -94.69 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.37 | |||||
| Quick Ratio | 0.37 | |||||
| Cash Ratio | 0.29 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -6.7 | |||||
| Shareholder Yield % | -512.28 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROA % | -147.07 | |||||
| ROIC % | -234.95 | |||||
| 3-Year ROIIC % | -216.92 | |||||
| ROC (Joel Greenblatt) % | -1262.8 | |||||
| ROCE % | -271.32 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -0.86 | |||||
| EV-to-EBITDA | -0.88 | |||||
| EV-to-FCF | -1.27 | |||||
| Price-to-GF-Value | 0.11 | |||||
| Earnings Yield (Greenblatt) % | -115.75 | |||||
| FCF Yield % | -874.61 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
GeNeuro SA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.59 | ||
| Beta | -0.02 | ||
| 3-Year Sharpe Ratio | -0.67 | ||
| 3-Year Sortino Ratio | -0.84 | ||
| Volatility % | 135.44 | ||
| 14-Day RSI | 53.73 | ||
| 14-Day ATR (€) | 0.039632 | ||
| 20-Day SMA (€) | 0.068035 | ||
| 12-1 Month Momentum % | -94.69 | ||
| 52-Week Range (€) | 0.0266 - 2.42 | ||
| Shares Outstanding (Mil) | 29.6 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
GeNeuro SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
GeNeuro SA Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
GeNeuro SA Frequently Asked Questions
What is GeNeuro SA(FRA:GEM)'s stock price today?
The current price of FRA:GEM is €0.10. The 52 week high of FRA:GEM is €2.42 and 52 week low is €0.03.
When is next earnings date of GeNeuro SA(FRA:GEM)?
The next earnings date of GeNeuro SA(FRA:GEM) is .
Does GeNeuro SA(FRA:GEM) pay dividends? If so, how much?
GeNeuro SA(FRA:GEM) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers